Medicare Enrolled

Dr. Margaret Curran, M.D.

Rheumatology · Hendersonville, NC
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
800 N JUSTICE ST, Hendersonville, NC 28791
8646961000
In practice since 2006 (19 years)
NPI: 1629149364 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Curran from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Curran? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Curran

Dr. Margaret Curran is a rheumatology specialist in Hendersonville, NC, with 19 years of NPI registration. Based on federal Medicare data, Dr. Curran performed 83,497 Medicare services across 559 unique beneficiaries.

Between the years covered by Open Payments, Dr. Curran received a total of $9,018 from 52 pharmaceutical and/or device companies across 349 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Curran is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 26% volume in NC $9,018 industry payments

Medicare Practice Summary

Medicare Utilization ↗
83,497
Medicare services
Top 26% in NC for rheumatology
559
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,395 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Tocilizumab injection (Actemra) 41,486 $5 $14
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
25,510 $10 $50
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
8,200 $34 $100
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
5,325 $25 $110
Denosumab injection (Prolia/Xgeva) 1,620 $18 $31
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
528 $84 $250
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
233 $93 $265
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
213 $48 $130
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
148 $21 $75
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
104 $11 $30
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
47 $60 $175
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
44 $111 $320
Steroid injection (triamcinolone)
A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered.
26 $1 $5
Injection, methylprednisolone acetate, 40 mg 13 $6 $19
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
47.3% high complexity
52.0% medium
0.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$9,018
Total received (2018-2024)
Avg $1,288/year across 7 years
Top 29% in NC for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
349
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,961 (88.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,057 (11.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,760
2023
$1,189
2022
$788
2021
$552
2020
$1,629
2019
$1,449
2018
$651

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$387
Janssen Biotech, Inc.
$270
UCB, Inc.
$264
ABBVIE INC.
$223
GlaxoSmithKline, LLC.
$220
Mallinckrodt Hospital Products Inc.
$197
AstraZeneca Pharmaceuticals LP
$182
Organon Llc
$166
PFIZER INC.
$126
Novartis Pharmaceuticals Corporation
$110
Octapharma USA, Inc.
$104
ANI Pharmaceuticals, Inc.
$95
Lilly USA, LLC
$85
Boehringer Ingelheim Pharmaceuticals, Inc.
$57
Sandoz Inc.
$56
SCILEX PHARMACEUTICALS INC.
$48
Alexion Pharmaceuticals, Inc.
$40
Genentech USA, Inc.
$35
SOBI, INC
$29
Kiniksa Pharmaceuticals International, plc
$24
Celgene Corporation
$17
Abbott Laboratories
$13
Actelion Pharmaceuticals US, Inc.
$12
Top 3 companies account for 33.4% of 2024 payments
All-time payments by company (2018-2024) ›
Horizon Therapeutics plc
$1,099
Amgen Inc.
$1,091
Janssen Biotech, Inc.
$747
UCB, Inc.
$719
GlaxoSmithKline, LLC.
$676
PFIZER INC.
$557
AstraZeneca Pharmaceuticals LP
$333
Novartis Pharmaceuticals Corporation
$313
ABBVIE INC.
$308
Octapharma USA, Inc.
$295
Boehringer Ingelheim Pharmaceuticals, Inc.
$272
Mallinckrodt Hospital Products Inc.
$248
Alexion Pharmaceuticals, Inc.
$214
Lilly USA, LLC
$196
AbbVie Inc.
$171
ANI Pharmaceuticals, Inc.
$170
Organon Llc
$166
Janssen Scientific Affairs, LLC
$130
EISAI INC.
$125
Organon LLC
$97
Celgene Corporation
$87
Merck Sharp & Dohme Corporation
$85
GENZYME CORPORATION
$79
Incyte Corporation
$68
SOBI, INC
$68
Genentech USA, Inc.
$58
Sandoz Inc.
$56
Bayer HealthCare Pharmaceuticals Inc.
$51
SCILEX PHARMACEUTICALS INC.
$48
Grifols USA, LLC
$46
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$35
Pharmacyclics LLC, An AbbVie Company
$31
TerSera Therapeutics LLC
$30
Abbott Laboratories
$30
Ipsen Biopharmaceuticals, Inc
$24
Kiniksa Pharmaceuticals International, plc
$24
Ultragenyx Pharmaceutical Inc.
$23
Astellas Pharma US Inc
$22
AbbVie, Inc.
$22
TOLMAR Pharmaceuticals, Inc.
$21
Aurinia Pharma U.S., Inc.
$21
Mylan Institutional Inc.
$20
Secura Bio, Inc.
$19
Sun Pharmaceutical Industries Inc.
$17
Dova Pharmaceuticals
$15
Exeltis, USA Inc.
$15
Helsinn Therapeutics (U.S.), Inc.
$15
Daiichi Sankyo Inc.
$13
Actelion Pharmaceuticals US, Inc.
$12
Takeda Pharmaceuticals U.S.A., Inc.
$12
Seattle Genetics, Inc.
$12
E.R. Squibb & Sons, L.L.C.
$11
Top 3 companies account for 32.6% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADCETRIS · AKYNZEO · Actemra · Alphanate · Arcalyst · BENLYSTA · COSENTYX · Cimzia · Crysvita · Doptelet · ELIGARD · EMEND · EVENITY · Enbrel · FARYDAK · Fulphila · GILOTRIF · Gamunex-C · HADLIMA · HUMIRA · HYRIMOZ · Humira · IMBRUVICA · INFLECTRA · INJECTAFER · Imbruvica · JAKAFI · JEVTANA · KEVZARA · KINERET · KRYSTEXXA · Kineret · Kyprolis · LUPKYNIS · Lenvima · Neulasta · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OPSUMIT · ORENCIA · Otezla · PROCLAIM · PROMACTA · PURIFIED CORTROPHIN GEL · Prolia · Quzyttir · RELISTOR · REMICADE · RENFLEXIS · RINVOQ · Revlimid · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · SOLIRIS · SOMATULINE DEPOT · STELARA · STRENSIQ · Strensiq · TALTZ · TAVNEOS · TREMFYA · Ultomiris · Vectibix · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XELJANZ · XOSPATA · Xofigo · YONSA (abiraterone acetate) · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Hendersonville?
Compare rheumatologists in the Hendersonville area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
15
Per 100K population
12.8
County median income
$67,623
Nearest hospital
PARDEE HOSPITAL HENDERSON COUNTY
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Curran is a mixed practice specialist, with above-average Medicare volume (top 26% in NC), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Curran experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Curran performed 41,486 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Curran receive payments from pharmaceutical companies?
Yes. Dr. Curran received a total of $9,018 from 52 companies across 349 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Curran's costs compare to other rheumatologists in Hendersonville?
Dr. Curran's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Curran) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →